Yee S W, Momozawa Y, Kamatani Y, Tyndale R F, Weinshilboum R M, Ratain M J, Giacomini K M, Kubo M
University of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA.
Clin Pharmacol Ther. 2016 Nov;100(5):423-426. doi: 10.1002/cpt.405. Epub 2016 Jul 21.
Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.
全基因组关联研究（GWAS）已鉴定出许多遗传性基因因素，这些因素是人类疾病风险或生理特征变异的基础。相比之下，尽管存在大量无法解释的个体间变异性，但针对药物反应表型的GWAS却较少。为满足这一迫切需求，美国国立卫生研究院药物基因组学研究网络（PGRN）和日本理化学研究所综合医学科学中心（IMS）支持了一项合作项目PGRN-RIKEN，其目标是加速对药物反应表型的GWAS研究。
